By ONN Staff

Articles

Addition of Polatuzumab Vedotin to R-CHP Reduces Risk of Disease Progression, Death in DLBCL

July 23, 2022

Phase 3 findings from the POLARIX trial showed that the addition of platuzumab vedotin to rituximab, cyclophosphamide, doxorubicin, and prednisone resulted in a 27% reduction in risk of disease progression, relapse, or death for patients with newly diagnosed diffuse large B-cell lymphoma.

Nurse Takeaways: 2022 ASCO Genitourinary Cancers Symposium at a Glance

April 21, 2022

PARP inhibitors emerge as frontline treatment in metastatic castration-resistant prostate cancer, immunotherapy combinations improve quality of life in advanced renal cell carcinoma, and antibody drug conjugates show promise in cisplatin-ineligible urothelial cancer.

2022 ASCO Gastrointestinal Cancers Symposium Highlights

April 20, 2022

Ivosidenib maintains quality of life in cholangiocarcinoma, immunotherapy outperforms chemotherapy in select gastric/gastroesophageal junction adenocarcinoma, and nivolumab induces high response rates are observed among patients with BRAF V600E–mutant metastatic colorectal cancer.